Bristol Myers Squibb (BMY) Equity Income (2009 - 2024)
Bristol Myers Squibb (BMY) reported Equity Income of -$23.0 million for Q3 2024, down 227.78% year-over-year from $18.0 million in Q4 2023, and down 182.14% on a QoQ basis from $28.0 million in Q2 2024.
Bristol Myers Squibb (BMY) has 15 years of Equity Income data on file, last reported at -$23.0 million in Q3 2024.
- Quarterly Equity Income fell 227.78% year-over-year to -$23.0 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $12.0 million (down 84.42% YoY) and the FY2019 annual result came in at -$4.0 million, down 104.3% from the prior year.
- Equity Income slipped to -$23.0 million in Q3 2024 per BMY's latest filing, from $28.0 million in the prior quarter.
- Across five years, Equity Income topped out at $40.0 million in Q3 2021 and bottomed at -$23.0 million in Q3 2024.
- The 4-year median for Equity Income is $23.0 million (2023), against an average of $13.7 million.
- Peak annual rise in Equity Income reached 354.55% in 2024, while the deepest fall reached 227.78% in 2024.
- Tracing BMY's Equity Income over 4 years: stood at $30.0 million in 2020, then jumped by 33.33% to $40.0 million in 2021, then slumped by 55.0% to $18.0 million in 2023, then slumped by 227.78% to -$23.0 million in 2024.
- Per Business Quant, the three latest BMY Equity Income figures stand at -$23.0 million (Q3 2024), $28.0 million (Q2 2024), and $18.0 million (Q3 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | - |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -23.00 Mn |
| Jun 30, 2024 | 28.00 Mn |
| Sep 30, 2023 | 18.00 Mn |
| Jun 30, 2023 | -11.00 Mn |
| Sep 30, 2021 | 40.00 Mn |
| Sep 30, 2020 | 30.00 Mn |
| Dec 31, 2019 | -4.00 Mn |
| Dec 31, 2018 | 20.00 Mn |
| Sep 30, 2018 | 22.00 Mn |
| Jun 30, 2018 | 27.00 Mn |
| Mar 31, 2018 | 24.00 Mn |
| Dec 31, 2017 | 16.00 Mn |
| Sep 30, 2017 | 21.00 Mn |
| Jun 30, 2017 | 20.00 Mn |
| Mar 31, 2017 | 18.00 Mn |
| Dec 31, 2016 | 12.00 Mn |
| Sep 30, 2016 | 19.00 Mn |
| Jun 30, 2016 | 20.00 Mn |
| Mar 31, 2016 | 26.00 Mn |
| Dec 31, 2015 | 16.00 Mn |
| Sep 30, 2015 | 19.00 Mn |
| Jun 30, 2015 | 22.00 Mn |
| Mar 31, 2015 | 26.00 Mn |
| Dec 31, 2014 | 26.00 Mn |
| Sep 30, 2014 | 12.00 Mn |
| Jun 30, 2014 | 33.00 Mn |
| Mar 31, 2014 | 36.00 Mn |
| Dec 31, 2013 | 38.00 Mn |
| Sep 30, 2013 | 42.00 Mn |
| Jun 30, 2013 | 50.00 Mn |
| Mar 31, 2013 | 36.00 Mn |
| Dec 31, 2012 | 33.00 Mn |
| Sep 30, 2012 | 40.00 Mn |
| Jun 30, 2012 | 53.00 Mn |
| Mar 31, 2012 | 57.00 Mn |
| Dec 31, 2011 | 66.00 Mn |
| Sep 30, 2011 | 71.00 Mn |
| Jun 30, 2011 | 62.00 Mn |
| Mar 31, 2011 | 82.00 Mn |
| Dec 31, 2010 | 61.00 Mn |
| Sep 30, 2010 | 70.00 Mn |
| Jun 30, 2010 | 85.00 Mn |
| Mar 31, 2010 | 97.00 Mn |
| Dec 31, 2009 | 115.00 Mn |
| Sep 30, 2009 | 139.00 Mn |
| Jun 30, 2009 | 150.00 Mn |
| Mar 31, 2009 | 146.00 Mn |